Shanghai Bio-Heart Biological Technology Co., Ltd. Class H (2185) AI Stock Analysis

• Market Cap: HK$1.45B
• Dividend Yield: N/A
• Average Volume (3M): 2.14M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.62
• Revenue Growth: N/A
• EPS Growth: 22.65%
• Country: HK
• Employees: 63
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.12
• Shares Outstanding: 235,703,410
• 10 Day Avg. Volume: 3,698,147
• 30 Day Avg. Volume: 2,141,365
• PEG Ratio: 0.09
• Price to Book (P/B): 0.57
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.25
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 44 Neutral
• Price Target: HK$5.50 ▼(-3.68% Downside)

The score is held down primarily by the lack of revenue and ongoing cash burn despite improving losses, alongside weak technical momentum (below key moving averages with negative MACD). Low leverage is a stabilizing factor, but valuation is difficult to assess with negative earnings and no dividend data.

Positive Factors

Product Registration

The registration of the Iberis® RDN System in New Zealand enhances the company's market reach and potential revenue streams, marking a significant step in global expansion and product adoption.

Strategic Partnership

The strategic partnership with Biosensors International Group strengthens market presence in Europe, Asia-Pacific, and Latin America, potentially driving long-term growth and competitive positioning.

Market Expansion

The first procedure in Switzerland signifies progress in global market expansion, positioning the company as a leader in the renal denervation market, which can drive sustained growth and market share.

Negative Factors

Cash Burn

Ongoing cash burn poses a risk to financial stability, potentially requiring additional funding and impacting long-term operational sustainability if not addressed.

Lack of Revenue

The absence of revenue limits earnings visibility and quality, making the company highly dependent on future commercialization for profitability and long-term success.

Negative Returns on Equity

Negative returns on equity indicate ongoing value erosion, which can hinder investor confidence and long-term capital growth unless profitability improves.

Shanghai Bio-Heart Biological Technology Co., Ltd. Class H Business Overview & Revenue Model

Company Description

Shanghai Bio-heart Biological Technology Co., Ltd. operates as an interventional cardiovascular device company in the People's Republic of China. The company focuses on the provision of bioresorbable scaffolds (BRS) and renal denervation (RDN) therapies for the treatment of coronary artery diseases and uncontrolled and resistant hypertension. It is developing Bioheart, a BRS system used in percutaneous coronary intervention procedures for the treatment of coronary artery disease; Iberis 2nd, a multi-electrode RDN product candidate; and drug coated balloon, a sirolimus drug-eluting balloon catheter designed for instent restenosis. The company has collaboration agreements with Terumo (China) Investment Co., Ltd. to conduct clinical trials for Iberis 2nd. Shanghai Bio-heart Biological Technology Co., Ltd. was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.

How the Company Makes Money

Shanghai Bio-Heart Biological Technology Co., Ltd. generates revenue by developing and selling medical devices and technologies related to cardiovascular health. The company earns income through the sale of its proprietary products to healthcare providers, hospitals, and clinics. Additionally, it may engage in partnerships or licensing agreements with other medical technology firms or research institutions to co-develop new products or expand market reach. Revenues are also supported by ongoing research and development efforts that lead to new innovations and solutions in the cardiovascular sector.

Shanghai Bio-Heart Biological Technology Co., Ltd. Class H Financial Statement Overview

Summary

Shanghai Bio-Heart Biological Technology Co., Ltd. faces significant financial challenges typical of early-stage biotech firms. With zero revenue, the company consistently reports net losses. Despite a strong equity base and low leverage, the persistent negative cash flows and absence of revenue-generating activities are major financial risks.

Income Statement

The company has consistently reported zero revenue across all periods, resulting in negative gross profit, EBIT, and net income. This indicates a lack of revenue-generating activities, which is critical for sustainability and profitability. The persistent net losses highlight a significant financial risk, typical for early-stage biotech firms without marketable products.

Balance Sheet

The company maintains a strong equity base, with stockholders' equity consistently exceeding total liabilities, resulting in a healthy equity ratio. The debt-to-equity ratio is low, indicating minimal reliance on debt financing. However, the shrinking total assets and equity over time suggest potential financial strain if revenue generation does not commence.

Cash Flow

Operating and free cash flows are consistently negative, reflecting ongoing operational challenges and a cash burn typical of biotech firms in the pre-revenue stage. The lack of free cash flow growth and negative operating cash flow relative to net income highlight cash management risks.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	20.86M	0.00	0.00	0.00	0.00	0.00
Gross Profit	9.70M	0.00	-23.60M	-24.25M	0.00	-9.71M
EBITDA	-44.18M	-44.54M	-148.21M	-237.34M	-400.88M	-319.76M
Net Income	-89.33M	-87.94M	-194.36M	-237.50M	-361.45M	-365.79M
Balance Sheet
Total Assets	878.42M	733.78M	817.90M	981.52M	1.11B	785.04M
Cash, Cash Equivalents and Short-Term Investments	312.87M	202.39M	369.44M	451.32M	708.53M	453.67M
Total Debt	7.67M	8.28M	1.76M	18.11M	22.45M	1.32M
Total Liabilities	224.62M	53.24M	44.04M	66.47M	80.04M	40.94M
Stockholders Equity	477.65M	660.47M	748.41M	883.21M	995.69M	700.09M
Cash Flow
Free Cash Flow	-83.34M	-166.69M	-66.74M	-170.65M	-147.28M	-60.74M
Operating Cash Flow	-59.77M	-119.55M	-49.03M	-140.62M	-105.45M	-54.28M
Investing Cash Flow	-23.02M	-46.03M	-28.86M	-100.69M	-33.73M	-225.15M
Financing Cash Flow	-1.22M	-2.44M	-5.82M	-35.18M	383.68M	722.99M

Shanghai Bio-Heart Biological Technology Co., Ltd. Class H Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 5.71
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2185, the sentiment is Positive. The current price of 5.71 is below the 20-day moving average (MA) of 5.90, below the 50-day MA of 6.71, and above the 200-day MA of 5.15, indicating a neutral trend. The MACD of -0.15 indicates Negative momentum. The RSI at 52.87 is Neutral, neither overbought nor oversold. The STOCH value of 85.95 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2185.

Shanghai Bio-Heart Biological Technology Co., Ltd. Class H Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
1875	61 Neutral	HK$1.93B	238.10	0.99%	―	9.41%	-32.69%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
6998	50 Neutral	HK$5.20B	58.33	2.04%	―	1447.56%	―
6622	47 Neutral	HK$1.85B	-6.12	-14.84%	―	-38.38%	-22.12%
2511	46 Neutral	HK$1.38B	-3.89	-67.27%	―	―	47.42%
2185	44 Neutral	HK$1.45B	-14.99	-14.87%	―	―	22.65%
6978	43 Neutral	HK$1.71B	-6.43	―	―	―	27.90%

Shanghai Bio-Heart Biological Technology Co., Ltd. Class H Corporate Events

Shanghai Bio-heart Registers Iberis® RDN System in New Zealand

Shanghai Bio-heart Biological Technology Co., Ltd. has announced the successful registration of its Iberis® Multi-Electrode Renal Artery Radiofrequency Ablation Catheter System in New Zealand. This system is notable for being the only renal denervation product approved globally with both transradial and transfemoral approaches, aiming to make renal denervation procedures safer, more effective, and cost-efficient, with the ultimate goal of facilitating outpatient procedures worldwide.

Shanghai Bio-heart’s Iberis® RDN System Gains UK Registration

Shanghai Bio-heart Biological Technology Co., Ltd. announced the successful registration of its Iberis® RDN system with the UK’s Medicines & Healthcare products Regulatory Agency. This development, supported by a strategic partnership with Biosensors International Group, Ltd., enhances the company’s market presence across Europe, Asia-Pacific, and Latin America. The Iberis® RDN system is noted for being the only globally approved renal denervation product with both transradial and transfemoral approaches, offering safer and more cost-effective outpatient procedures.

Shanghai Bio-heart Achieves Milestone with First Iberis® RDN System Procedure in Switzerland

Shanghai Bio-heart Biological Technology Co., Ltd. has announced the successful completion of the first commercial procedure using its Iberis® Multi-Electrode Renal Artery Radiofrequency Ablation Catheter System in Switzerland, marking a significant milestone in its global expansion strategy. This development, supported by a strategic partnership with Biosensors International Group, Ltd., positions the company as a leader in the renal denervation market, with its system being the only one approved globally for both transradial and transfemoral approaches, potentially enhancing safety, efficacy, and cost-effectiveness of outpatient procedures.

Shanghai Bio-heart’s Controlling Shareholder to Boost Stake

Shanghai Bio-heart Biological Technology Co., Ltd. announced that its controlling shareholder, Philip Li Wang, plans to increase his shareholding in the company by purchasing additional H shares through Winning Powerful Limited, a company wholly owned by him. This move, estimated to involve up to HK$15 million, reflects Mr. Wang’s confidence in the company’s growth potential and long-term business prospects, while ensuring the company maintains a sufficient public float of shares.